| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 3,200 | ₹3.15 23.52% | 2,7500% |
| 2500% | ₹354.55 0% | 3,250 | ₹5.2 40.54% | 1,75016.66% |
| 1,25066.66% | ₹285.7 -7.68% | 3,300 | ₹8 37.93% | 16,50010% |
| 7500% | ₹264.3 0% | 3,350 | ₹13.25 56.8% | 8,50021.42% |
| 6,0000% | ₹260.15 0% | 3,400 | ₹19.9 52.49% | 30,50011.92% |
| 75050% | ₹157.2 -8.49% | 3,450 | ₹29.3 48.73% | 12,5006.38% |
| 23,0003.37% | ₹123.1 -27.2% | 3,500 | ₹43 44.53% | 48,500-7.17% |
| 36,500-0.68% | ₹95.5 -27.15% | 3,550 | ₹62.15 44.03% | 10,000-6.97% |
| 1,71,7500.88% | ₹67.15 -32.17% | 3,600 | ₹85.7 40.26% | 63,250-22.15% |
| 65,7506.47% | ₹49 -33.91% | 3,650 | ₹115.05 34.48% | 14,000-18.84% |
| 89,000140.54% | ₹34 -34.92% | 3,700 | ₹155.05 34.65% | 4,750-9.52% |
| 15,0009.09% | ₹22.75 -39.25% | 3,750 | ₹141.05 0% | 6,2500% |
| 45,250-1.09% | ₹15.05 -41.43% | 3,800 | ₹215.05 14.38% | 2,00060% |
| 8,2506.45% | ₹10.5 -41.34% | 3,850 | ₹257.1 0% | 2500% |
| 27,2505.82% | ₹7.05 -43.14% | 3,900 | ₹293.25 0% | 1,0000% |
| 1,0000% | ₹8.05 0% | 3,950 | ₹355.8 0% | 2500% |
| 5,00025% | ₹3.55 -42.74% | 4,000 | ₹399 0% | 2500% |
| 2500% | ₹3 0% | 4,100 | - | - |
Torrent Urja, is a wholly owned subsidiary of Torrent Green Energy Pvt. Ltd. The company is incorporated to develop a solar-plus-wind power project.
The transaction involves around 38.75 lakh shares, priced at ₹1,600 each, being offloaded by JB Chemicals employees who recently converted their stock options.
The acquisition values JB Chemicals at ₹25,689 crore on a fully diluted basis, according to the company’s official announcement.
On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
